Drug comparison · Mood stabilizers

Lamictal vs Depakote

A clinical comparison of lamotrigine and valproate — two anticonvulsants widely used as mood stabilizers, with very different side-effect profiles and safety considerations.

Lamictal

Lamictal

lamotrigine

Anticonvulsant Mood stabilizer Voltage-gated Na⁺ channel blocker Weight-neutral
Depakote

Depakote

valproate / valproic acid

Anticonvulsant Mood stabilizer GABA modulator Major teratogen

Side-by-side

Comparison table

Feature Lamictal (lamotrigine) Depakote (valproate)
Drug class Anticonvulsant / mood stabilizer Anticonvulsant / mood stabilizer
Mechanism Blocks voltage-gated Na⁺ channels; reduces glutamate release Increases GABA; blocks voltage-gated Na⁺/Ca²⁺ channels; inhibits histone deacetylase
Bipolar use Maintenance — especially for depressive episodes Acute mania; less evidence for maintenance
Epilepsy use Partial & generalized seizures; Lennox-Gastaut Absence, myoclonic, complex partial seizures
Migraine prevention No Yes — FDA approved
Weight effect Neutral Significant gain
Teratogenicity Lower risk — not a major teratogen Major teratogen — neural tube defects, fetal valproate syndrome
Rash / SJS risk Significant — requires slow titration Not prominent
Hepatotoxicity Not prominent Yes — especially in young children
Hair loss Not reported Common
Tremor Uncommon Common (dose-related)
Sedation Mild Moderate
Blood monitoring Levels available; LFTs periodically Levels + LFTs + CBC required regularly
Drug interactions Moderate — valproate doubles levels; OCP reduces levels Extensive — inhibits multiple CYP enzymes
Generic available Yes Yes
Pancreatitis risk Not reported Rare but reported

FDA-approved uses

Approved indications

Lamictal (lamotrigine)

  • Epilepsy — adjunctive therapy for partial seizures (adults & children ≥2 yr)
  • Epilepsy — primary generalized tonic-clonic seizures
  • Lennox-Gastaut syndrome (adjunctive)
  • Bipolar I disorder — maintenance treatment to delay recurrence of mood episodes, particularly depression

Depakote (valproate)

  • Epilepsy — complex partial seizures (monotherapy & adjunctive)
  • Epilepsy — absence seizures, myoclonic seizures (Depakene/Stavzor forms)
  • Bipolar disorder — acute manic or mixed episodes
  • Migraine prevention (Depakote ER)
  • ⚠ Contraindicated in pregnancy for migraine; avoid in women of childbearing potential without effective contraception

Formulations

Available strengths

Lamictal (lamotrigine)

Immediate-release tablets

Standard tablets
25 mg 50 mg 100 mg 150 mg 200 mg
Chewable / dispersible
2 mg 5 mg 25 mg
Extended-release (Lamictal XR)
25 mg 50 mg 100 mg 200 mg 250 mg 300 mg

Depakote (valproate)

Multiple formulations

Depakote (delayed-release tablets)
125 mg 250 mg 500 mg
Depakote ER (extended-release)
250 mg 500 mg
Depakote sprinkle capsules
125 mg
Depakene (valproic acid capsules/syrup)
250 mg capsule 250 mg/5 mL syrup

Safety

Important warnings

Black box warning — Lamictal

Serious skin reactions (Stevens-Johnson syndrome / TEN)

Lamotrigine (Lamictal) carries a risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) — rare but potentially fatal skin reactions. The risk is highest when:

  • The drug is started at too high a dose or titrated too quickly
  • Lamictal is combined with valproate (which nearly doubles lamotrigine blood levels)
  • The patient is a child (pediatric patients have higher rates of severe rash)

Any new rash during the first 8 weeks of treatment must be reported to a prescriber immediately. Lamictal must be titrated very slowly — typically over 6–8 weeks — to minimize rash risk. Abrupt discontinuation should be avoided as it can trigger seizures.

Clinical perspective

Key differences

Pregnancy safety: Lamictal is substantially safer

This is the most clinically significant difference between the two drugs. Depakote is a major teratogen that causes neural tube defects, fetal valproate syndrome, and lasting neurodevelopmental harm. Lamictal is not classified as a major teratogen and is generally preferred for people of childbearing potential who need an anticonvulsant or mood stabilizer. No anticonvulsant is fully safe in pregnancy, but the risk gap between these two drugs is very large.

Weight: Depakote causes significant gain; Lamictal is neutral

Valproate is one of the more weight-promoting medications in psychiatry. Weight gain is dose-related and often persistent. Lamotrigine does not cause meaningful weight gain on average — a notable advantage for long-term use, given the metabolic risks of excess weight in psychiatric populations who may already have elevated cardiovascular risk.

Bipolar phase coverage: different strengths, different phases

Depakote is better established for acute manic episodes — it can act relatively quickly and has robust trial data for mania. Lamictal is better for bipolar depression and maintenance; it is one of the few mood stabilizers with clear evidence for the depressive phase of bipolar I, which is where patients spend the majority of their symptomatic time. Patients who cycle between both poles often require combination therapy.

Drug interactions: Depakote interacts more broadly

Valproate inhibits multiple drug-metabolizing enzymes and displaces protein-bound drugs, creating a broad interaction profile. The most clinically significant interaction is with lamotrigine itself: adding valproate to a Lamictal regimen roughly doubles lamotrigine levels, substantially increasing rash risk and requiring immediate dose adjustment. Lamotrigine's level is also lowered by enzyme-inducing anticonvulsants (carbamazepine, phenytoin) and by oral contraceptive pills — a consideration for women on hormonal contraception.

Blood monitoring requirements differ

Both drugs require blood level monitoring, but Depakote demands more: valproate levels, liver function tests, and complete blood counts are recommended at baseline and periodically throughout treatment, especially in the first 6 months. Hepatotoxicity is a serious risk with valproate in young children and in patients on polypharmacy. Lamictal monitoring is less intensive — serum levels are available but not always routinely required, though liver function tests are checked periodically.

Common questions

Frequently asked questions

Is Lamictal or Depakote safer in pregnancy?
Depakote (valproate) is a major teratogen and is generally contraindicated in pregnancy. It significantly increases the risk of neural tube defects (including spina bifida), fetal valproate syndrome, and lower IQ in exposed children. The FDA has assigned it Category X for migraine prevention in pregnancy and Category D for epilepsy use. Lamictal (lamotrigine) carries a much lower teratogenic risk — it is not considered a major teratogen, and many clinicians consider it one of the safer anticonvulsant options for people who may become pregnant. Neither drug is completely risk-free in pregnancy; all treatment decisions should be made with a physician who can weigh the risks of uncontrolled seizures or mood episodes against medication exposure.
Which causes more weight gain — Lamictal or Depakote?
Depakote (valproate) is associated with significant weight gain, one of its most commonly reported side effects. The mechanism involves increased appetite and possible effects on insulin sensitivity. Lamictal (lamotrigine) is considered weight-neutral — clinical trials show it does not cause meaningful weight gain on average, and some patients report modest weight loss. For patients concerned about weight, Lamictal has a clear advantage in this area.
Which is better for bipolar disorder — Lamictal or Depakote?
They address different phases of bipolar disorder. Depakote (valproate) has strong evidence for treating acute manic episodes and is FDA-approved for that indication. Lamictal (lamotrigine) is FDA-approved for maintenance treatment of bipolar I disorder — specifically to delay the recurrence of depressive episodes. Head-to-head, Lamictal performs better for bipolar depression while Depakote performs better for mania. Many bipolar patients need treatment that addresses both phases; the best choice depends on which phase is more problematic for the individual and on other factors such as pregnancy risk, weight concerns, and tolerability.
What is Stevens-Johnson syndrome, and why does Lamictal carry that risk?
Stevens-Johnson syndrome (SJS) is a rare but potentially life-threatening skin reaction characterized by blistering and peeling of the skin and mucous membranes. Lamictal (lamotrigine) carries a small but real risk of SJS and a related condition, toxic epidermal necrolysis (TEN). The risk is highest when the drug is started at too high a dose or increased too quickly — which is why Lamictal must be titrated very slowly over several weeks. Rash occurring early in treatment should be reported to a prescriber immediately. The risk is also higher when Lamictal is combined with valproate (Depakote), which raises lamotrigine blood levels and requires an even slower titration schedule.
Do Lamictal and Depakote interact with each other?
Yes — and the interaction is clinically significant. Valproate (Depakote) inhibits the enzyme that metabolizes lamotrigine, roughly doubling lamotrigine blood levels. This substantially increases the risk of Lamictal side effects, including the rash that can precede Stevens-Johnson syndrome. When the two drugs are used together, the starting dose of Lamictal and the titration schedule must be adjusted downward. A prescriber and pharmacist must coordinate closely when these drugs are co-prescribed.
Does Depakote cause hair loss?
Yes. Hair loss (alopecia) is a recognized and relatively common side effect of valproate (Depakote). It typically appears as diffuse thinning rather than focal hair loss. It is often dose-related and may improve with dose reduction. Some patients find that supplementing with zinc and selenium helps, though evidence for this is limited. Lamictal is not associated with hair loss.

Explore more

💊 Seroquel vs Abilify 💊 Lexapro vs Zoloft 💊 Wellbutrin vs Lexapro 💊 Cymbalta vs Effexor 💊 Xanax vs Klonopin 📋 All comparisons